Latest Insider Transactions at Eli Lilly & CO (LLY)
This section provides a real-time view of insider transactions for Eli Lilly & CO (LLY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ELI LILLY & Co to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ELI LILLY & Co's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 10
2025
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Grant, award, or other acquisition
|
Direct |
18,771
+12.08%
|
$16,293,228
$868.88 P/Share
|
|
Feb 10
2025
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Open market or private sale
|
Direct |
5,000
-1.37%
|
$4,320,000
$864.14 P/Share
|
|
Feb 10
2025
|
Anat Hakim EVP, GC & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
10,320
+26.36%
|
$8,957,760
$868.88 P/Share
|
|
Feb 10
2025
|
David A Ricks President, Chair, and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
55,131
+9.27%
|
$47,853,708
$868.88 P/Share
|
|
Feb 06
2025
|
Lilly Endowment Inc |
SELL
Open market or private sale
|
Direct |
210,000
-0.01%
|
$183,960,000
$876.89 P/Share
|
|
Feb 01
2025
|
David A Ricks President, Chair, and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,903
-2.4%
|
$9,653,333
$811.08 P/Share
|
|
Feb 01
2025
|
David A Ricks President, Chair, and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
26,561
+5.08%
|
-
|
|
Feb 01
2025
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
SELL
Payment of exercise price or tax liability
|
Direct |
4,003
-3.15%
|
$3,246,433
$811.08 P/Share
|
|
Feb 01
2025
|
Daniel Skovronsky EVP, CSO & Pres. LRL & LLY Imm |
BUY
Exercise of conversion of derivative security
|
Direct |
8,989
+6.62%
|
-
|
|
Feb 01
2025
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
SELL
Payment of exercise price or tax liability
|
Direct |
1,409
-9.48%
|
$1,142,699
$811.08 P/Share
|
|
Feb 01
2025
|
Jacob Van Naarden EVP & Pres., Lilly Oncology |
BUY
Exercise of conversion of derivative security
|
Direct |
3,023
+16.9%
|
-
|
|
Feb 01
2025
|
Anne E. White EVP & Pres, Lilly Neuroscience |
SELL
Payment of exercise price or tax liability
|
Direct |
1,457
-2.12%
|
$1,181,627
$811.08 P/Share
|
|
Feb 01
2025
|
Anne E. White EVP & Pres, Lilly Neuroscience |
BUY
Exercise of conversion of derivative security
|
Direct |
3,269
+4.53%
|
-
|
|
Feb 01
2025
|
Ilya Yuffa EVP & President, LLY Int'l |
SELL
Payment of exercise price or tax liability
|
Direct |
1,434
-6.22%
|
$1,162,974
$811.08 P/Share
|
|
Feb 01
2025
|
Ilya Yuffa EVP & President, LLY Int'l |
BUY
Exercise of conversion of derivative security
|
Direct |
3,269
+12.41%
|
-
|
|
Feb 01
2025
|
Anat Hakim EVP, GC & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
2,166
-10.47%
|
$1,756,626
$811.08 P/Share
|
|
Feb 01
2025
|
Anat Hakim EVP, GC & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
4,904
+19.17%
|
-
|
|
Feb 01
2025
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,281
-3.83%
|
$1,038,891
$811.08 P/Share
|
|
Feb 01
2025
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
2,861
+7.87%
|
-
|
|
Feb 01
2025
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
SELL
Payment of exercise price or tax liability
|
Direct |
1,535
-3.2%
|
$1,244,885
$811.08 P/Share
|
|
Feb 01
2025
|
Patrik Jonsson EVP&Pres, CardMetHlth, LLY USA |
BUY
Exercise of conversion of derivative security
|
Direct |
3,433
+6.67%
|
-
|
|
Feb 01
2025
|
Diogo Rau EVP & CIDO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,466
-10.2%
|
$1,188,926
$811.08 P/Share
|
|
Feb 01
2025
|
Diogo Rau EVP & CIDO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,269
+18.53%
|
-
|
|
Jan 21
2025
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.03%
|
$11,130
$742.35 P/Share
|
|
Jan 21
2025
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.02%
|
$9,646
$742.35 P/Share
|
|
Jan 21
2025
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
13
+0.68%
|
$9,646
$742.35 P/Share
|
|
Jan 21
2025
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
19
+0.12%
|
$14,098
$742.35 P/Share
|
|
Jan 21
2025
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
6
+0.24%
|
$4,452
$742.35 P/Share
|
|
Dec 16
2024
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.39%
|
$9,348
$779.0 P/Share
|
|
Dec 16
2024
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
19
+0.12%
|
$14,801
$779.0 P/Share
|
|
Dec 16
2024
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.47%
|
$9,348
$779.0 P/Share
|
|
Dec 16
2024
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
15
+0.03%
|
$11,685
$779.0 P/Share
|
|
Dec 16
2024
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
12
+0.63%
|
$9,348
$779.0 P/Share
|
|
Nov 18
2024
|
Karen Walker Director |
BUY
Grant, award, or other acquisition
|
Direct |
302
+4.61%
|
$219,554
$727.2 P/Share
|
|
Nov 18
2024
|
Jamere Jackson Director |
BUY
Grant, award, or other acquisition
|
Direct |
302
+3.19%
|
$219,554
$727.2 P/Share
|
|
Nov 18
2024
|
Kimberly H Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+4.79%
|
$229,005
$727.2 P/Share
|
|
Nov 18
2024
|
William G Kaelin Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
302
+1.39%
|
$219,554
$727.2 P/Share
|
|
Nov 18
2024
|
Juan R Luciano Director |
BUY
Grant, award, or other acquisition
|
Direct |
322
+0.98%
|
$234,094
$727.2 P/Share
|
|
Nov 18
2024
|
Gabrielle Sulzberger Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+5.65%
|
$229,005
$727.2 P/Share
|
|
Nov 18
2024
|
Ralph Alvarez Director |
BUY
Grant, award, or other acquisition
|
Direct |
318
+0.29%
|
$231,186
$727.2 P/Share
|
|
Nov 18
2024
|
Katherine Baicker Director |
BUY
Grant, award, or other acquisition
|
Direct |
302
+1.29%
|
$219,554
$727.2 P/Share
|
|
Nov 18
2024
|
J Erik Fyrwald Director |
BUY
Grant, award, or other acquisition
|
Direct |
320
+0.44%
|
$232,640
$727.2 P/Share
|
|
Nov 18
2024
|
Mary Lynne Hedley Director |
BUY
Grant, award, or other acquisition
|
Direct |
315
+7.38%
|
$229,005
$727.2 P/Share
|
|
Nov 08
2024
|
Donald A Zakrowski SVP, Finance, & CAO |
SELL
Open market or private sale
|
Direct |
900
-14.11%
|
$722,700
$803.38 P/Share
|
|
Nov 01
2024
|
Lucas Montarce EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
467
-4.05%
|
$382,006
$818.93 P/Share
|
|
Nov 01
2024
|
Lucas Montarce EVP & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,074
+8.51%
|
-
|
|
Nov 01
2024
|
Eric Dozier EVP, Chief People Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
681
-7.81%
|
$557,058
$818.93 P/Share
|
|
Nov 01
2024
|
Eric Dozier EVP, Chief People Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,534
+14.95%
|
-
|
|
Nov 01
2024
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
750
-2.39%
|
$613,500
$818.93 P/Share
|
|
Nov 01
2024
|
Edgardo Hernandez EVP & Pres., Mfg. Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
1,687
+5.1%
|
-
|